Physician profile
Christopher Chapman
NPI 1164426888
$8,840.69
in general payments reported to CMS, 2019-2025
36 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $1,426 · 2021: $1,797 · 2022: $1,483 · 2023: $1,094 · 2024: $1,141 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.81 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,404.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,073.98 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $992.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $546.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $512.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.11 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $426.40 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $385.80 | 2019-2025 | |
| Dexcom, INC. | $333.17 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $305.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.31 | 2020-2025 | Xifaxan |
| Amgen INC. | $278.38 | 2021-2025 | Evenity, Otezla, Repatha |
| Vertiflex, INC. | $227.91 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $226.74 | 2022 | |
| Allergan, INC. | $199.57 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $165.68 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $151.96 | 2019-2021 | |
| Antares Pharma, INC. | $150.05 | 2020-2023 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $129.77 | 2019-2024 | Freestyle Libre 3, Proclaim |
| Boston Scientific Corporation | $109.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.51 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.58 | 2021 | |
| Genentech USA, INC. | $54.34 | 2021 | |
| Astellas Pharma US INC | $45.86 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $31.27 | 2025 | Eylea Hd |
| Philips North America LLC | $27.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.81 | 2025 | |
| Medtronic, INC. | $23.17 | 2024 | Venaseal |
| Biotronik INC. | $19.22 | 2020 | |
| Exact Sciences Corporation | $18.57 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2022 | |
| Phadia US INC. | $17.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.72 | 2023 | |
| Esperion Therapeutics, INC. | $14.32 | 2020 | |
| Hikma Pharmaceuticals USA | $14.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.